Evidence map›Paper›PMID 22797919›Full record

ArticleJournal of cell science2012

PKD2 and PKD3 promote prostate cancer cell invasion by modulating NF-κB- and HDAC1-mediated expression and activation of uPA.

Zhipeng Zou, Fangyin Zeng, Wanfu Xu, Chunxia Wang, Zhiyong Ke, Q Jane Wang, Fan Deng

Open access · bronzeAbstract read
In one paragraph

Article in Journal of cell science, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Golgi Drivers of Cancer.Sub-cellular biochemistry · 2026
    Review
  5. Article
  6. Article
  7. BRAT1 - a new therapeutic target for glioblastoma.Cellular and molecular life sciences : CMLS · 2025
    Article
  8. Article
  9. Circadian rhythm disruption and endocrine-related tumors.World journal of clinical oncology · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Potential role for protein kinase D inhibitors in prostate cancer.Journal of molecular medicine (Berlin, Germany) · 2023
    Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Zhipeng ZouDepartment of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
Fangyin Zeng
Wanfu Xu
Chunxia Wang
Zhiyong Ke
Q Jane Wang
Fan Deng
Southern Medical University · CNNanfang Hospital · CNUniversity of Pittsburgh · US

Funding

The role of PKD3 in prostate carcinogenesisR01CA129127 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, QIMING JANE · 2009 to 2013
$1.5M
Development of small molecule inhibitors of protein kinase DR01CA142580 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, QIMING JANE · 2010 to 2014
$1.5M
NCI NIH HHS R01 CA129127NCI NIH HHS R01 CA142580
6 · The paper itself

Abstract

Although protein kinase D3 (PKD3) has been shown to contribute to prostate cancer cell growth and survival, the role of PKD in prostate cancer cell motility remains unclear. Here, we show that PKD2 and PKD3 promote nuclear factor kappa B (NF-κB) signaling and urokinase-type plasminogen activator (uPA) expression/activation, which are crucial for prostate cancer cell invasion. Silencing of endogenous PKD2 and/or PKD3 markedly decreased prostate cancer cell migration and invasion, reduced uPA and uPA receptor (uPAR) expression and increased plasminogen activator inhibitor-2 (PAI-2) expression. These results were further substantiated by the finding that PKD2 and PKD3 promoted the activity of uPA and matrix metalloproteinase 9 (MMP9). Furthermore, depletion of PKD2 and/or PKD3 decreased the level of binding of the p65 subunit of NF-κB to the promoter of the gene encoding uPA (PLAU), suppressing transcriptional activation of uPA. Endogenous PKD2 and PKD3 interacted with inhibitor of NF-κB (IκB) kinase β (IKKβ); PKD2 mainly regulated the phosphorylated IKK (pIKK)-phosphorylated IκB (pIκB)-IκB degradation cascade, p65 nuclear translocation, and phosphorylation of Ser276 on p65, whereas PKD3 was responsible for the phosphorylation of Ser536 on p65. Conversely, inhibition of uPA transactivation by PKD3 silencing was rescued by constitutive Ser536 p65 phosphorylation, and reduced tumor cell invasion resulting from PKD2 or PKD3 silencing was rescued by ectopic expression of p65. Interestingly, PKD3 interacted with histone deacetylase 1 (HDAC1), suppressing HDAC1 expression and decreasing its binding to the uPA promoter. Moreover, depletion of HDAC1 resulted in recovery of uPA transactivation in PKD3-knockdown cells. Taken together, these data suggest that PKD2 and PKD3 coordinate to promote prostate cancer cell invasion through p65 NF-κB- and HDAC1-mediated expression and activation of uPA.

Indexed as

Histone Deacetylase 1Protein Kinase CTranscription Factor RelATRPP Cation ChannelsUrokinase-Type Plasminogen ActivatorCell Line, TumorGene Expression Regulation, NeoplasticHumansMaleMatrix Metalloproteinase 9Neoplasm InvasivenessPhosphorylationProstatic NeoplasmsSignal TransductionTranscriptional ActivationHDAC1 protein, humanHistone Deacetylase 1Matrix Metalloproteinase 9MMP9 protein, humanProtein Kinase Cprotein kinase C nuTranscription Factor RelATRPP Cation ChannelsUrokinase-Type Plasminogen Activator

Identifiers

PMID22797919
PMCPMC4074284
OpenAlexW1996709851

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.